CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
复发或转移性鼻咽癌的免疫治疗
英文原题：Immunotherapy for recurrent or metastatic nasopharyngeal carcinoma.
查看英文原题
Immunotherapy for recurrent or metastatic nasopharyngeal carcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
免疫治疗，特别是免疫检查点抑制剂（ICIs），如抗程序性死亡1/程序性死亡配体1（PD-1/PD-L1）治疗，已成为包括复发或转移性鼻咽癌（R/M-NPC）在内的实体瘤的关键治疗方式。尽管ICIs的应用取得了进展，但仍有进一步改善患者结局的空间。R/M-NPC免疫治疗的另一个有前景的方法涉及过继细胞治疗（ACT），旨在激发全身性抗肿瘤免疫。然而，针对树突状细胞（DCs）的单一药物疗法似乎仍处于临床试验阶段。本综述强调了免疫治疗作为R/M-NPC患者治疗范式中有价值的辅助手段的潜力。需要进一步研究，通过实施联合治疗和克服免疫抑制等策略来提高免疫治疗的疗效。此外，开发基于生物标志物的评分系统对于识别适合精准免疫治疗的候选者至关重要。
展开英文摘要原文
Immunotherapy, particularly immune checkpoint inhibitors (ICIs), such as anti-programmed death 1/programmed death-ligand 1 (PD-1/PD-L1) therapy, has emerged as a pivotal treatment modality for solid tumors, including recurrent or metastatic nasopharyngeal carcinoma (R/M-NPC). Despite the advancements in the utilization of ICIs, there is still room for further improving patient outcomes. Another promising approach to immunotherapy for R/M-NPC involves adoptive cell therapy (ACT), which aims to stimulate systemic anti-tumor immunity.
However, individual agent therapies targeting dendritic cells (DCs) appear to still be in the clinical trial phase. This current review underscores the potential of immunotherapy as a valuable adjunct to the treatment paradigm for R/M-NPC patients.
Further research is warranted to enhance the efficacy of immunotherapy through the implementation of strategies such as combination therapies and overcoming immune suppression.
Additionally, the development of a biomarker-based scoring system is essential for identifying suitable candidates for precision immunotherapy.
论文信息
- 作者
- Liu X、Shen H、Zhang L、Huang W、Zhang S、Zhang B
- 第一作者单位
- The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China.China
- 通讯作者单位
- The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China. xld_Jane_Eyre@126.com.China
- 文献类型
- 综述
- 期刊
- NPJ precision oncology2024 May 16
- 原文标识
- PubMed 38755255 · DOI 10.1038/s41698-024-00601-1
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →